Rafael Holdings reported fourth-quarter and full-year fiscal 2026 results and highlighted a regulatory milestone for Cyclo Therapeutics: the company submitted an application seeking U.S. approval of remibetadex, its treatment candidate for Niemann-Pick disease type C (NPC). The release also noted a new nonproprietary name for the drug and an Alzheimer’s disease license secured earlier in the year.
Key details
- FDA application submitted: Cyclo Therapeutics submitted the application on October 28, seeking approval of remibetadex—marketed in development as Trappsol® Cyclo™—for the neurovisceral manifestations of NPC in adults and children, including patients from birth. The compound was previously referred to as intravenous hydroxypropyl-β-cyclodextrin.
- Trial results were mixed: The application is supported in part by the Phase 3 TransportNPC study, completed in June 2026. The study did not meet its primary endpoint in the overall patient population (p=0.19).
- A prespecified subgroup showed a signal: Among patients receiving background miglustat and/or leucine therapy, a prespecified analysis found 71% slowing of disease progression (p=0.046). The application also includes an overall-survival analysis comparing patients with matched registry controls.
- Voucher requested: Cyclo’s application asks for a rare pediatric disease priority review voucher. The announcement does not say whether the request has been granted.
- New drug name: The U.S. Adopted Names Council assigned the compound the nonproprietary name “remibetadex.”
- Alzheimer’s disease license: In April 2026, Cyclo entered an exclusive, worldwide license with the Massachusetts Institute of Technology to use hydroxypropyl-β-cyclodextrin in Alzheimer’s disease.
- Financial results: Rafael said it reported results for the quarter and fiscal year ended July 31, 2026. The material provided here does not include revenue, earnings, cash or other financial figures.
Plain-English implications
The NPC application is a regulatory step, not an approval. The pivotal trial missed its primary endpoint across the overall study population, while a prespecified subgroup analysis showed a favorable result; the application also relies on a comparison with registry controls for survival. Those distinctions are central to the evidence supporting the request.